Ginkgo Bioworks Holdings, Inc. DNA

Company Overview

Ginkgo Bioworks Holdings, Inc. is a U.S.-based biotechnology company focused on synthetic biology and cell programming. The company operates primarily in the biotechnology, life sciences, industrial biology, and biosecurity sectors. Ginkgo develops platforms that enable customers to engineer microorganisms and biological systems for applications across pharmaceuticals, agriculture, industrial chemicals, food ingredients, consumer products, and environmental solutions. Its core business model centers on providing research and development services through its programmable cell platform while also generating downstream value through partnerships, licensing arrangements, milestone payments, royalties, and equity interests in customer programs.

The company’s primary revenue drivers include its Cell Engineering platform and Biosecurity services. Ginkgo has positioned itself as a horizontal platform company rather than a single-product biotechnology developer, allowing it to support multiple industries simultaneously. Founded in 2008 by a group of Massachusetts Institute of Technology scientists, the company evolved from an academic synthetic biology venture into a publicly traded platform business following its merger with a special purpose acquisition company in 2021. Its strategic positioning is supported by large-scale biological data generation, automated laboratory infrastructure, and partnerships with pharmaceutical, agriculture, and industrial companies.